文献速递生殖医学

基于人工智能的供卵卵母细胞质量评估可适度改善囊胚发育预测:迈向卵母细胞捐赠治疗管理更高个体化的第一步

Artificial intelligence-based donor oocyte quality assessment moderately improves the prediction of blastocyst development: a first step towards higher personalization in the management of egg donation treatments.
PubMed 文献 · Hum Reprod · 2025-01-01

前瞻性、观察性、多中心、盲法队列研究纳入3个IVF中心145名供者的1179枚新鲜MII卵母细胞,分配至171对受者夫妇。AI衍生的Magenta评分与受精(OR 1.08)和囊胚形成(OR 1.19)显著相关,单独AUC为0.6,联合供者年龄达0.62,再联合精子活力1%增幅和培养基达0.65;预测至少一次活产的10%概率增幅与真实累积活产率显著相关(OR 1.55;AUC 0.691)。

要点

  • Magenta评分较高的卵母细胞2PN受精(OR 1.08)和囊胚形成(OR 1.19)率显著较高,独立于混杂因素。
  • Magenta评分单独AUC为0.6,联合供者年龄0.62,再联合精子活力1%增幅和培养基0.65。
  • 82%的周期实际囊胚数落在或高于根据Magenta评分外推的预测范围。

核心结论

  • AI衍生的Magenta评分与受精、囊胚形成显著相关,有助于估计累积活产率,但在一部分周期中观察到高估趋势。
  • 作者认为AI评估供卵卵母细胞是提高捐赠周期卵母细胞分配个体化和公平性的有前景工具,但AI预测应与供者、受者和周期特异性变量整合。

研究设计与样本

  • 前瞻性、观察性、多中心、盲法队列研究,纳入2023年6月至2024年10月间3个IVF中心的145名供者的1179枚新鲜MII卵母细胞,分配至171对受者夫妇。
  • 裸化MII卵母细胞在200-400×放大下成像,使用基于AI的评分系统(Magenta Score,Future Fertility)评估。
  • 主要结局为Magenta评分与囊胚发育的关联,校正供者年龄、精子活力和培养基。

主要发现

  • Magenta评分较高的卵母细胞2PN受精(OR 1.08)和囊胚形成(OR 1.19)率显著较高,独立于混杂因素。
  • Magenta评分单独AUC为0.6,联合供者年龄达0.62,再联合男性伴侣精子活力1%增幅和所用培养基达0.65。
  • 82%的病例实际囊胚数落在或高于根据各队列Magenta评分外推的预测范围。
  • 基于Magenta评分预测至少一次活产概率增加10%与真实累积活产率显著较高相关(OR 1.55;AUC 0.691)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 观察性设计无法进行因果推断。
  • 仅评估新鲜卵母细胞周期,限制了对玻璃化卵母细胞的外推。
  • 部分供者卵母细胞被冷冻保存并排除于分析之外。
  • 需要未来随机试验评估AI主动用于分配决策时的临床效用。
  • 需要进一步改进和前瞻性验证以提高预测准确性并避免高估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can an artificial intelligence (AI)-based oocyte scoring system reliably predict the developmental competence of fresh donor oocytes? SUMMARY ANSWER: The AI-derived Magenta Score was significantly associated with fertilization, blastocyst formation, and helpful to estimate cumulative live birth rates, although a trend toward overestimation was observed in a subset of cycles. WHAT IS KNOWN ALREADY: Oocyte quality is a critical determinant of IVF success; however, standardized and objective methods for its assessment are lacking. Current allocation strategies in oocyte donation cycles often neglect recipient-related factors and risk overproduction of surplus embryos. AI-based evaluation may offer a more objective, reproducible alternative to traditional morphology-based assessment. STUDY DESIGN, SIZE, DURATION: Prospective, observational, multicenter, blinded cohort study including 1179 fresh metaphase II (MII) oocytes from 145 donors, allocated to 171 recipient couples across three IVF centers between June 2023 and October 2024. PARTICIPANTS/MATERIALS, SETTING, METHODS: Denuded MII oocytes were imaged at 200-400× magnification and assessed using an AI-based scoring system (Magenta Score, Future Fertility). The primary outcome was the association between Magenta Score and blastocyst development, adjusted for donor age, sperm motility, and culture medium. Secondary outcomes included associations with oocyte dysmorphisms, fertilization, blastocyst quality and timing, implantation, cumulative live birth rates, and accuracy of blastocyst yield predictions. MAIN RESULTS AND THE ROLE OF CHANCE: Oocytes with higher Magenta Scores had significantly higher rates of 2PN fertilization (odds ratio [OR] 1.08) and blastocyst formation (OR 1.19), independent of confounders. Magenta Score per se displayed an AUC of 0.6, reaching 0.62 if combined with donors' age and 0.65 if also combined with male partners' sperm motility 1%-increase and culture medium used, highlighting the multifactorial nature of embryo development. In 82% of cases, the actual blastocyst number fell within or above the predicted range extrapolated from the Magenta Scores of each cohort. A 10% increase in the predicted probability of achieving at least one live birth based on the Magenta Score was associated with a significantly higher true cumulative live birth rate (OR 1.55; AUC 0.691). LIMITATIONS, REASONS FOR CAUTION: The observational design precludes causal inference. Only fresh oocyte cycles were evaluated, limiting extrapolation to vitrified oocytes. Some donor oocytes were cryopreserved and excluded from analysis. Future randomized trials are needed to assess clinical utility when AI is actively used for allocation decisions. WIDER IMPLICATIONS OF THE FINDINGS: AI-based assessment of donor oocytes offers a promising tool to enhance the personalization and fairness of oocyte allocation in donation cycles. However, to maximize its clinical value, AI predictions should be integrated with additional donor-, recipient-, and cycle-specific variables. Further refinements and prospective validations are necessary to improve prediction accuracy and avoid overestimation, ultimately optimizing cumulative live birth rates while minimizing surplus embryo production. STUDY FUNDING/COMPETING INTEREST(S): No funding. N.M., J.F., D.N., and A.K. are employees and hold stock options of Future Fertility, the company that developed the AI model used. All other authors report no conflict of interest related with the content of this manuscript. TRIAL REGISTRATION NUMBER: n/a.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Cimadomo D, Badajoz V, Hebles M, et al. Artificial intelligence-based donor oocyte quality assessment moderately improves the prediction of blastocyst development: a first step towards higher personalization in the management of egg donation treatments. Hum Reprod. 2025. PMID: 40759152. doi:10.1093/humrep/deaf153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。